Doheny Asset Management CA Sells 26,210 Shares of RxSight, Inc. (NASDAQ:RXST)

Doheny Asset Management CA decreased its holdings in shares of RxSight, Inc. (NASDAQ:RXST) by 40.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 39,300 shares of the company’s stock after selling 26,210 shares during the period. RxSight accounts for about 1.0% of Doheny Asset Management CA’s holdings, making the stock its 28th largest holding. Doheny Asset Management CA owned about 0.10% of RxSight worth $1,351,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Telemark Asset Management LLC raised its position in RxSight by 6.6% during the 4th quarter. Telemark Asset Management LLC now owns 321,000 shares of the company’s stock valued at $11,036,000 after purchasing an additional 20,000 shares during the last quarter. Swiss National Bank raised its position in shares of RxSight by 2.6% in the 4th quarter. Swiss National Bank now owns 66,300 shares of the company’s stock worth $2,279,000 after acquiring an additional 1,700 shares in the last quarter. AlphaQuest LLC raised its position in shares of RxSight by 65.7% in the 4th quarter. AlphaQuest LLC now owns 5,086 shares of the company’s stock worth $175,000 after acquiring an additional 2,017 shares in the last quarter. Aigen Investment Management LP bought a new position in shares of RxSight in the 4th quarter worth approximately $407,000. Finally, Victory Capital Management Inc. raised its position in shares of RxSight by 4.7% in the 4th quarter. Victory Capital Management Inc. now owns 271,978 shares of the company’s stock worth $9,351,000 after acquiring an additional 12,114 shares in the last quarter. Institutional investors own 78.78% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently issued reports on RXST shares. Needham & Company LLC reissued a “buy” rating and issued a $43.00 target price on shares of RxSight in a research report on Wednesday, February 26th. Stifel Nicolaus decreased their target price on RxSight from $35.00 to $33.00 and set a “hold” rating for the company in a research report on Wednesday, February 26th. JPMorgan Chase & Co. cut their price target on RxSight from $62.00 to $40.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 26th. UBS Group assumed coverage on RxSight in a research note on Friday, December 6th. They issued a “buy” rating and a $52.00 price target on the stock. Finally, Wells Fargo & Company cut their price target on RxSight from $40.00 to $35.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 26th. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, RxSight currently has a consensus rating of “Moderate Buy” and a consensus price target of $51.63.

RxSight Trading Up 2.5 %

Shares of RXST opened at $25.84 on Friday. The business’s fifty day simple moving average is $30.56 and its two-hundred day simple moving average is $41.20. RxSight, Inc. has a 12 month low of $24.64 and a 12 month high of $66.54. The company has a market cap of $1.05 billion, a price-to-earnings ratio of -31.13 and a beta of 1.22.

RxSight (NASDAQ:RXST) last issued its earnings results on Tuesday, February 25th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of $0.10 by ($0.25). RxSight had a negative net margin of 23.92% and a negative return on equity of 14.00%. The business had revenue of $40.21 million for the quarter, compared to analysts’ expectations of $40.23 million. As a group, research analysts forecast that RxSight, Inc. will post -0.7 EPS for the current year.

Insider Activity

In other news, Director Jesse Anderson Corley purchased 1,443 shares of the stock in a transaction dated Wednesday, January 15th. The shares were purchased at an average cost of $31.18 per share, with a total value of $44,992.74. Following the acquisition, the director now directly owns 1,443 shares of the company’s stock, valued at $44,992.74. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Tamara Fountain sold 7,000 shares of the stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $25.71, for a total value of $179,970.00. Following the transaction, the director now directly owns 24,793 shares in the company, valued at $637,428.03. The trade was a 22.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 9.36% of the company’s stock.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.